Skip to main content

View Resource

Published

Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studies.
van Haren FMP. eClinicalMedicine 2025;:https://doi.org/10.1016/j.eclinm.2025.103339.
[Inhaled nebulised unfractionated heparin (UFH) has a strong rationale as a treatment for severe respiratory infections, including COVID-19, due to its antiviral, anti-inflammatory, and anti-coagulant properties, which may prevent viral entry, lung injury progression, and pulmonary thrombosis. In patients hospitalised but not intubated for COVID-19, inhaled nebulised UFH prevented intubation and reduced mortality, without causing pulmonary or systemic bleeding.]
Freely available online
Age Groups
Adults
Older People
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Hospital Ward
Intensive Care
Staff Groups
Drug Therapy